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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER97Home Monitoring for Heart Failure ManagementAnh L. Bui, Gregg C. Fonarow
Close to 1 million heart failure (HF) hospitalizations occur annually in the United States,
with the majority of these resulting from worsening congestion in patients previously
diagnosed with HF. Bui and Fonarow review the need to develop and implement more
effective strategies to assess, monitor, and treat HF in the outpatient setting. Earlier
identification and treatment of congestion together with improved care coordination,
management of comorbid conditions, and enhanced patient self-management may help to
prevent hospitalizations. This paper discusses the challenges in monitoring patients with HF,
reviews clinical trials testing different monitoring strategies in HF, and highlights ongoing
investigations into the optimal approaches to home monitoring for HF.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY105DES Appear Superior to BMS in Patients >85 Years of AgeTracy Y. Wang, Frederick A. Masoudi, John C. Messenger, Kendrick A. Shunk, Andrew Boyle,
J. Matthew Brennan, H. Vernon Anderson, Kevin J. Anstrom, David Dai, Eric D. Peterson,
Pamela S. Douglas, John S. Rumsfeld
Despite an aging population, little is known about the comparative effectiveness of drug-
eluting stents (DES) versus bare-metal stents (BMS) in patients 85 years of age undergoing
percutaneous coronary intervention (PCI). Wang and colleagues reviewed data from 471,006
subjects 65 years of age who underwent PCI. Patients 85 years of age comprised an
increasing proportion of PCIs, yet rates of DES use declined the most in this age group.
Compared with BMS, DES was associated with lower mortality, however, the adjusted
mortality difference narrowed with increasing age. In contrast, the adjusted HR for
myocardial infarction rehospitalization was significantly lower with DES and the benefit
increased with age. These results suggest improved outcomes with DES compared to BMS in
patients 85 years of age.(continued on page A-31)
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113ecreasing Rates of Vascular Complications for Percutaneous
Aortic Valve ReplacementStefan Toggweiler, Ronen Gurvitch, Jonathon Leipsic, David A. Wood, Alexander B. Willson,
Ronald K. Binder, Anson Cheung, Jian Ye, John G. Webb
Toggweiler and colleagues evaluated the frequency of vascular complications in a consecutive
patient population undergoing transfemoral percutaneous aortic valve replacement (PAVR)
applying the recently developed Valve Academic Research Consortium definitions. PAVR
was performed in 137 consecutive patients in 2009 to 2010. All but 1 patient underwent
planned arteriotomy closure utilizing a percutaneous pre-closure technique. Smaller sheaths,
rigorous angiographic and computed tomographic screening, and percutaneous vascular repair
techniques were increasingly used over this period. There was a decrease in major vascular
complications from 8% to 1%, minor vascular complications decreased from 24% to 8%,
major bleeds fell from 14% to 1%, and unplanned surgery decreased from 28% to 2%.
With careful patient selection, advanced interventional techniques, and a fully percutaneous
procedure, marked reductions in vascular and bleeding complications can be achieved.TRANSCATHETER TREATMENT OF VALVE DISEASE
119eformation Dynamics and Mechanical Properties of the Aortic Annulus
With Implications for Transcatheter Aortic Valve TherapyAshraf Hamdan, Victor Guetta, Eli Konen, Orly Goitein, Amit Segev, Ehud Raanani, Dan Spiegelstein,
Ilan Hay, Elio Di Segni, Michael Eldar, Ehud Schwammenthal
Hamdan and colleagues used 256-slice computed tomography to assess deformation dynamics
and in vivo mechanical properties of the aortic annulus throughout the cardiac cycle in
patients with aortic stenosis. The aortic annulus plane was reconstructed in 10% increments of
the RR interval. In both subjects with normal and with calcified aortic valves the minimum
diameter increased in systole by approximately 10% and the ellipticity index decreased, but
there were no significant changes in perimeter. These results show that the aortic annulus,
generally elliptic, assumes a more round shape in systole, thus increasing the cross-sectional
area without a substantial change in perimeter. Aortic annulus perimeter appears, therefore,
ideally suited for accurate sizing in transcatheter aortic valve implantation.
Editorial Comment: Carlos E. Ruiz, page 128(continued on page A-32)
JANUARY 10, 2012 (continued) A-32PTRANSCATHETER TREATMENT OF VALVE DISEASE130MitraClip Device for High-Surgical-Risk Patients With Mitral RegurgitationPatrick L. Whitlow, Ted Feldman, Wes R. Pedersen, D. Scott Lim, Robert Kipperman, Richard Smalling,
Tanvir Bajwa, Howard C. Herrmann, John Lasala, James T. Maddux, Murat Tuzcu, Samir Kapadia,
Alfredo Trento, Robert J. Siegel, Elyse Foster, Donald Glower, Laura Mauri, Saibal Kar, on behalf of the
EVEREST II Investigators
The EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study (HRS)
assessed the safety and effectiveness of the MitraClip device (Abbott Vascular, Santa Clara,
California) in patients with significant mitral regurgitation (MR) at high risk of surgical
mortality. Patients with severe symptomatic MR and an estimated surgical mortality 12%
were enrolled. A comparator group of patients screened but not enrolled were identified
retrospectively. MitraClip devices were successfully placed in 96% of patients. The 30-day
procedure-related mortality was 7.7% in the HRS versus 8.3% in the comparator group. The
12-month survival was 76% in the HRS compared to 55% in the comparator group. There
were significant improvements in left ventricular end-diastolic volume, end-systolic volume,
and New York Heart Association functional class with the MitraClip Device.Editorial Comment: Zoltan G. Turi, Michael Rosenbloom, page 140HEART RHYTHM DISORDERS
143rocedural Complications, Rehospitalizations, and
Repeat Procedures After Catheter Ablation for AFRashmee U. Shah, James V. Freeman, David Shilane, Paul J. Wang, Alan S. Go, Mark A. Hlatky
Radiofrequency or cryotherapy ablation of atrial fibrillation (AF) is a relatively new treatment
option and data on post-procedural outcomes in large, general populations are limited. Shah
and colleagues used data from the California State Inpatient Database to identify all adult
patients who underwent their first AF ablation from 2005 to 2008. Among 4,156 patients
who underwent an initial AF ablation, 5% had peri-procedural complications, most
commonly vascular, and 9% were readmitted within 30 days. The rate of all-cause
hospitalization was 39% by 1 year. The rate of readmission for recurrent AF, atrial flutter,
and/or repeat ablation was 22% by 1 year and 30% by 2 years.
Editorial Comment: David E. Haines, page 150(continued on page A-33)
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153ET/MRI Imaging Sheds Lights on
Processes of Inflammation After Myocardial InfarctionWon Woo Lee, Brett Marinelli, Anja M. van der Laan, Brena Sena, Rostic Gorbatov, Florian Leuschner,
Partha Dutta, Yoshiko Iwamoto, Takuya Ueno, Mark P. V. Begieneman, Hans W. M. Niessen, Jan J. Piek,
Claudio Vinegoni, Mikael J. Pittet, Filip K. Swirski, Ahmed Tawakol, Marcelo Di Carli, Ralph Weissleder,
Matthias Nahrendorf
Lee and colleagues used advanced imaging techniques along with histological examination to
study post-myocardial infraction myocardial inflammation in both animal and human
subjects. Using fiducial landmarks for fusing positron emission tomography (PET)/computed
tomography and magnetic resonance imaging (MRI), areas of delayed gadolinium
enhancement from mice with coronary ligation showed high 18-fluorodeoxyglucose uptake.
Cell depletion and isolation data confirmed that this largely reflected inflammation. Further
experiments showed that there was a 5.6-fold increase in monocyte recruitment in the remote
myocardium, but cell recruitment in this area was delayed compared to the infarcted area.
These studies shed light on the innate inflammatory response in remote myocardium after
myocardial infarction.Editorial Comment: Stefan Frantz, Ulrich Hofmann, page 164PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH166Hemoglobin Directs Macrophage Differentiation and Prevents Foam Cell FormationAloke V. Finn, Masataka Nakano, Rohini Polavarapu, Vinit Karmali, Omar Saeed, XiaoQing Zhao,
Saami Yazdani, Fumiyuki Otsuka, Talina Davis, Anwer Habib, Jagat Narula, Frank D. Kolodgie,
Renu Virmani
Finn and colleagues studied selective macrophage differentiation in areas of intraplaque
hemorrhage using freshly isolated human monocytes, a rabbit model, and human
atherosclerotic plaques. The results showed that macrophages are stimulated by exposure to
hemoglobin and differentiate into a subclass which they term M(Hb). M(Hb) were
characterized by their resistance to cholesterol loading and upregulation of ATP-binding
cassette transporters, reduced intracellular iron, and reduced reactive oxygen species. These
results help us to better understand macrophage diversity and suggest the potential that
therapies aimed at altering iron homeostasis within macrophages may prevent foam cell
formation and atherosclerotic lesion progression.(continued on page A-34)
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EEXPEDITED PUBLICATIONS178New Onset of AF After TAVI Associated with High Risk of StrokeIgnacio J. Amat-Santos, Josep Rodés-Cabau, Marina Urena, Robert DeLarochellière, Daniel Doyle,
Rodrigo Bagur, Jacques Villeneuve, Mélanie Côté, Luis Nombela-Franco, François Philippon,
Philippe Pibarot, Eric Dumont
Amat-Santos and colleagues evaluated the incidence of and complications related to new-
onset atrial fibrillation (NOAF) after transcatheter aortic valve implantation (TAVI) in 138
patients with no prior history of atrial fibrillation (AF). NOAF was defined as any episode of
AF lasting 30 s. NOAF occurred in 32% of patients, with one-third of cases occurring
during the procedure. At 30-day follow-up, NOAF was associated with a higher rate of
stroke/systemic embolism (13.6% vs. 3.2%). All patients with a late stroke ( 24 h after the
rocedure), had at least 1 episode of AF. The risk of an embolic event was 40% in those with
OAF who did not receive anticoagulant therapy. This report highlights the risk associated
ith NOAF after TAVI.ditorial Comment: Bernard Iung, Dominique Himbert, Alec Vahanian, page 189
